Investors lose faith in Brazil
Brazil's benchmark Bovespa stockmarket index has fallen by 11% since January to become the world’s worst-performing market.

You would think that soaring energy, mineral and food prices would be good news for a commodity exporter such as Brazil, says Simon Constable in Barron’s. Yet the local stockmarket has been the world’s worst-performing this year. The benchmark Bovespa index has fallen by 11% since 1 January. October marked the fourth losing month in a row for Brazilian stocks, their worst showing since 2014. The real currency has lost 8% against the US dollar so far this year. Economic reform and the commodities boom had tempted in foreign investors, but now “you’ve got a lot of people who are giving up hope”, says Phillip Torres of Aegon Asset Management.
Brazil looks cheap on a cyclically adjusted price/earnings (Cape) ratio of 16.8, according to data from Mebane Faber of Cambria Investment Management. Yet this is no time to go bargain hunting. “A more challenging macro scenario” may see earnings forecasts cut, making currently low valuations deceptive, private banking firm Wealth High Governance tells Bloomberg.
The latest sell-off came as Brazil planned a spending splurge ahead of elections next year. The government of far-right president Jair Bolsonaro wants to spend $14bn on a new welfare programme, a plan that will breach a constitutional spending cap. As Michael Pooler explains in the Financial Times, the cap “limits budget increases in line with inflation and is regarded as a pillar of the country’s economic credibility”. Four senior economic officials have resigned in protest.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dangerous debt
Brazil can ill-afford a new spending splurge, says Desmond Lachman for The Hill. A Covid-19-induced recession sent the country’s budget deficit up to a record 10% of GDP last year and saw public debt top 100% of GDP. That far exceeds the 70% level that emerging markets try to avoid hitting for fear of “a public debt crisis”. The real’s plunge at a time of “ample global liquidity” is especially worrying; a gradual tightening of US monetary policy means the real’s woes could just be beginning. The independent central bank faces a horrible “dilemma” between “losing control of inflation” and hiking rates to levels that create serious economic pain. It has so far chosen the latter option, raising interest rates 5.75% since March, making it the world’s most hawkish monetary authority.
Bolsonaro’s approval ratings have sunk to new lows, says the Financial Times. A bungled pandemic response has left 600,000 Brazilians dead. He faces a growing thicket of legal investigations, but it is economic mismanagement that may prove “the most potent threat” to his re-election prospects. Never mind the recovery – in Brazil an outright economic contraction may be on the cards next year. “The 2022 elections cannot come quickly enough.”
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Reeves warned against property tax shake-up – 3 ways it could backfire on first-time buyers
Rachel Reeves reportedly has her eye on high-end property taxes in the upcoming Budget, but there are concerns a shake-up could unintentionally hamper those trying to get on the housing ladder
-
Average Brits want to retire five years before they can – who has the widest retirement gap?
Brits are expecting to work for longer than ever but there are big disparities in the number of extra working years predicted. A small tweak could help close the gap
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?